Otezla (apremilast) is not a traditional immunosuppressant. It works differently from drugs that broadly suppress the immune system, and one major clinical review notes that because apremilast is not immunosuppressive, it may be preferred for immunocompromised patients. That said, it does modulate immune activity, which places it in a gray area that’s worth understanding.
How Otezla Actually Works
Otezla belongs to a class called PDE4 inhibitors. PDE4 is an enzyme that breaks down a signaling molecule called cAMP inside your cells. When Otezla blocks that enzyme, cAMP levels rise, and this shift dials down certain inflammatory signals while boosting some anti-inflammatory ones. The result is a targeted adjustment of your immune response rather than a broad shutdown.
Traditional immunosuppressants, like methotrexate or cyclosporine, work by suppressing large portions of the immune system. Biologic drugs target specific immune proteins (like TNF, a key driver of inflammation) by blocking them directly. Otezla sits upstream of all that. Instead of blocking one immune protein or suppressing immune cells outright, it adjusts the internal signaling inside those cells so they produce less inflammation on their own. This is why many clinicians call it an immunomodulator rather than an immunosuppressant.
What the Infection Data Shows
The clearest way to judge whether a drug meaningfully suppresses your immune system is to look at infection rates. A pooled analysis of 15 clinical trials covering nearly 5,000 patients found that serious infections occurred in 0.3% of people taking Otezla, compared to 0.4% of people taking a placebo. In other words, people on Otezla were no more likely to develop serious infections than people taking a sugar pill. That’s a stark contrast to traditional immunosuppressants and many biologics, which carry measurably higher infection risks and often require regular blood monitoring to catch immune suppression early.
Less Monitoring Than Immunosuppressants
If you’ve taken methotrexate or a biologic, you’re familiar with frequent blood draws to check liver function, white blood cell counts, or kidney markers. Otezla requires far less of this. Expert guidelines recommend a standard blood test before starting treatment and then a complete blood count once or twice a year. Routine drug monitoring isn’t necessary, which is another signal that the drug isn’t suppressing your immune system in the way traditional therapies do.
Side Effects to Expect
Otezla’s most common side effects are gastrointestinal, not immune-related. In psoriasis trials, 17% of patients experienced diarrhea and 17% experienced nausea. These symptoms tend to be most noticeable in the first few weeks and often improve over time. In Behçet’s disease trials, diarrhea rates were higher, affecting about 41% of patients.
Weight loss is another notable effect. In psoriasis trials, 12% of patients lost between 5% and 10% of their body weight, and 2% lost 10% or more. For psoriatic arthritis, about 10% of patients experienced 5% to 10% weight loss. This isn’t necessarily harmful, but it’s worth tracking, especially if you’re already at a lower weight.
Depression and mood changes have been flagged as a precaution. In clinical trials, about 1% to 1.3% of patients on Otezla reported depression, compared to 0.4% to 1% on placebo. The difference is small but worth being aware of, particularly if you have a history of mood disorders.
What Otezla Is Approved to Treat
The FDA has approved Otezla for three conditions: active psoriatic arthritis, plaque psoriasis in patients who are candidates for light therapy or systemic treatment, and oral ulcers associated with Behçet’s disease. It’s approved for adults across all three indications, and for children aged 6 and older (weighing at least 20 kg) for psoriatic arthritis and moderate to severe plaque psoriasis. It’s taken as a pill twice daily at a dose of 30 mg, which is a practical advantage over injectable biologics.
Why the Classification Gets Confusing
Some medical references do list apremilast under the broader umbrella of “immunosuppressive agents,” which is where the confusion comes from. The NIH’s StatPearls database, for instance, describes it as both a “selective immunosuppressant” and an “immunomodulatory” medication. This dual labeling reflects the fact that any drug influencing immune function can technically fall under immunosuppression in a pharmacological sense, even if it doesn’t suppress the immune system the way the term implies to most people.
The practical distinction matters most. Otezla doesn’t increase your risk of serious infections. It doesn’t require the kind of immune monitoring that drugs like methotrexate demand. And clinical guidelines specifically note it as an option for patients who may already be immunocompromised and need to avoid further immune suppression. For the question most people are really asking, “Will this drug make me more vulnerable to infections?”, the clinical evidence says no.